The inhaler, which is GSK’s top-selling product, is used for treating COPD, a lung disease comprised of chronic bronchitis and emphysema.
The approval was granted following a regulatory review of a clinical study known as TORCH, which investigated the drug’s use among patients with COPD.
Seretide, which is marketed as Advair in the United States, generated worldwide sales of GBP3.3 billion in 2006.